MindRank AI, a clinical-stage biotechnology company developing an artificial intelligence-powered drug research and development platform, announced that it has raised $52 million in Series B financing. The funding round was led by a group of institutional investors and healthcare-focused funds.
The new capital will be used to further develop MindRank’s proprietary Molecule Arts Platform (MAP) and advance the company’s portfolio of clinical-stage and preclinical drug candidates.
MindRank was founded to improve how innovative medicines are discovered and developed by integrating artificial intelligence throughout the pharmaceutical research process. The company’s MAP technology combines biology, chemistry, computation, laboratory evidence, and clinical data within a unified research and development system.
MAP is designed to support multiple stages of drug development, including target identification, molecular generation, candidate optimization, experimental validation, and clinical learning. The platform uses multi-agent AI systems, generative molecular design, computational biology, and experimental data to continuously refine its models and development strategies.
By connecting computational predictions with laboratory and clinical results, MindRank aims to make drug discovery more predictable, scalable, and capital-efficient. The company believes this integrated approach can reduce the time and resources required to identify and advance promising drug candidates.
MindRank’s lead clinical program is MDR-001, an oral small-molecule agonist targeting the glucagon-like peptide-1 receptor, commonly known as GLP-1. The drug candidate is currently being evaluated in Phase III clinical development in China.
MDR-001 entered Phase III development in 2025, approximately four and a half years after the project was initiated. MindRank said cumulative research and development spending from the program’s launch through the beginning of Phase III trials in China totaled approximately $23 million.
GLP-1 receptor agonists have emerged as an important class of medicines for treating metabolic conditions. Unlike many existing GLP-1 therapies that are administered through injections, MDR-001 is being developed as an oral small-molecule treatment.
Beyond MDR-001, MindRank has received three Investigational New Drug clearances in China and the United States. The company has also nominated five additional preclinical development candidates for advancement.
These programs are intended to demonstrate MAP’s capabilities across different stages of pharmaceutical research, from early molecular discovery and optimization through regulatory development and clinical testing.
The Series B financing will provide MindRank with additional resources to expand the capabilities of MAP, continue advancing MDR-001, and move other pipeline programs toward clinical development. The company also plans to strengthen the integration of computational models, experimental validation, and clinical findings across its drug development operations.
KEY QUOTE:
“Our goal is to translate advances in computation and artificial intelligence into better medicines for patients. By integrating biological, chemical, computational and clinical data into a continuously learning R&D engine, MAP is designed to make drug discovery and development more predictable, scalable and capital-efficient.”
Zhangming Niu, Founder and Chief Executive Officer of MindRank
